Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement

    New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement

    October 23, 2023
    October 23, 2023

    Download the PDF